Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, June 18, 2024 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 17, 2024 the Company bought 1200 (one thousand two hundred) own shares representing 0.00067% of the share capital of the Company, at a total value of BGN 7 112,00 on the Bulgarian Stock Exchange, the average price per share was BGN 5,94.
Sofia, Bulgaria, June 17, 2024 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 13, 2024 the Company sold 49 984 (forty nine thousand nine hundred eighty four) repurchased own shares representing 0.027% of the share capital of the Company, at a total value of BGN 298 002,32 on the Bulgarian Stock Exchange, the average price per share was BGN 5,97.
Sofia, Bulgaria, June 14, 2024 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 12, 2024 the Company sold 119 042 (one hundred nineteen thousand forty two) repurchased own shares representing 0.066% of the share capital of the Company, at a total value of BGN 713 019,96 on the Bulgarian Stock Exchange, the average price per share was BGN 5,99.
Sofia, Bulgaria, June 14, 2024 – According to the requirements of Art. 100t of LPOS, “Sopharma” AD (SFA: “BSE” AD, SPH: Warsaw Stock Exchange) notifies that the Company received a notification of shareholding from "Donev investments holding" AD, UIC 831915121, from which it is clear that with a share transaction with settlement on June 14, 2024 "Donev investments holding" AD increases its direct participation in the capital of the Company to 40.05% crossing the threshold of 40%.